In this episode of Topical Conversations, Graham Litchman, DO, MS, and Naiem Issa, MD, discuss the role of Janus kinase (JAK) inhibitors in atopic dermatitis (AD). These agents are increasingly valued for their efficacy and safety in clinical practice. A key advantage is the ability to individualize therapy through dose escalation, allowing JAK inhibitors to support a more personalized approach to managing this heterogeneous condition.
Safety considerations
Dr Litchman and Dr Issa review the safety profile of JAK inhibitors, noting that these medications are widely used and generally well tolerated. Large-scale studies of abrocitinib and upadacitinib, encompassing thousands of patients across multiple countries, support their safety and efficacy.
Dr Issa emphasizes the importance of proactively addressing the boxed warning during patient discussions. Many patients will review the package insert and raise concerns, so he begins the conversation by explaining the history and context behind the warning. The boxed warning stems from the ORAL Surveillance study of tofacitinib vs TNF inhibitors in patients with rheumatoid arthritis aged 50 and older with cardiovascular comorbidities; many of these patients were on concomitant methotrexate and often corticosteroids. This population differs significantly from typical patients with AD.
The “big 5” risks listed in the boxed warning (infection, major adverse cardiovascular events, thrombosis, sudden death, and malignancy) are framed as “reports” associated with JAK inhibitors, not as placebo-controlled findings. Dr Issa notes that clarifying this nuance helps patients understand the data in context and alleviates concerns. Dr Litchman adds that while these conversations can be complex, the majority of AD patients are not the same as the population studied in ORAL Surveillance, and most tolerate JAK inhibitors well in practice.
Personalized treatment and dosing strategies
Both experts highlight the role of JAK inhibitors in moving toward personalized medicine for AD, a heterogeneous and fluctuating disease. Treatment plans can be tailored based on individual patient needs, with the ability to adjust dosing when necessary.
Data from studies such as the JADE and LEVEL UP trials support flexible dosing. For example, abrocitinib can be initiated at 100 mg daily, with evidence supporting escalation to 200 mg if additional efficacy is needed. Upadacitinib has a similar dose-response profile, with starting doses of 15 mg and higher efficacy seen with 30 mg. Importantly, long-term safety data have not shown an increased risk of adverse events of special interest when escalating to higher doses.
In practice, Dr Issa often re-evaluates patients within 2 weeks, especially those with itch-dominant disease, and escalates dosing earlier if needed, supported by lab monitoring.
Biological and mechanistic insights
Beyond clinical outcomes, Dr Litchman highlights emerging data on gene expression changes with JAK inhibitors. Studies suggest that these therapies, like biologics, may help normalize core gene sets associated with AD, particularly those related to itch pathways and skin barrier function. Observing both clinical improvements in itch and skin clearance, alongside genomic changes, reinforces confidence in the biological rationale for JAK inhibitor therapy.
Key takeaways
For a closer look at how dose escalation can influence outcomes in practice, explore a case report authored by Graham Litchman, DO, MS. It details a 25-year-old patient with longstanding, refractory atopic dermatitis who achieved complete clearance on abrocitinib following dose adjustment, with before-and-after photos documenting the clinical response.
In this 45-minute symposium, expert faculty cover the latest updates for JAK inhibitors, including head-to-head efficacy and safety data for JAK inhibitors and biologics, and share clinical pearls for using JAK inhibitors in dermatology practice for atopic dermatitis."I can say that in my clinic, I am reaching for those high bars. You have toput yourself in the position of the patient or imagine that patient is your family member. Would you want mediocre treatment for them or average treatment or moderate treatment? You’d want them to get the best possible treatment. In my practice I’m now counseling patients 'yes we want clear skin. Yes, we want minimal itch. Yes we want your skin pain gone and for you to sleep better.'”- David Cotter, MD, PhDFC25: Charting the Course to Higher Targets With JAK Inhibition in Atopic Dermatitis: An Online ActivityThis activity is supported by an educational grant from AbbVie.
Don’t miss this Satellite Symposium from the 2025 Fall Clinical Dermatology Conference®, as Dr. Alexandra Golant, Dr. Mona Shahriari, and Dr. G. Michael Lewitt discuss IL-13 targeting biologics in the treatment of atopic dermatitis as well as strategies for optimizing their use.“To me, coming into an exam room in 2025, when we have so many different treatment options for these patients, it's a unique opportunity to use what we know about the data of these therapeutics and walk patients though their options and how to understand their disease state, and how to best choose the therapy that feels right for them.” – Alexandra Golant, MD FC25: Illuminate the Role of IL-13 Inhibitors for the Management of Atopic DermatitisThis activity is supported by an educational grant from Lilly.
“Of course we’re always starting with our basics: we’re using our gentle cleansers, our moisturization, our avoidance of known allergens or triggers, and then we're doing our topicals. But it can be very difficult if you have heavy stuff on your face or you’re required to put it on over and over. It can be really tough. So this paves the way really nicely to say it is time to move up, it is time to think about the next level, and typically the next step up is going to be a biologic agent.” - Peter Lio, MDA ‘HowTo’ activity delivers a short burst of engaging and compact content for learners to study at their own convenience. This microlearning activity is intended to provide practical insights from two experts on ‘HowTo’ improve care in head and neck atopic dermatitis in 10 minutes.This activity is supported by an educational grant from LEO Pharma.
This 30-minute symposium from the 2025 Pediatrics360 Virtual Conference takes a closer look at biologic therapies that can address the immune pathophysiology, associated comorbidities, and progression of moderate-to-severe atopic dermatitis in pediatric patients.“A lot of them (children with atopic dermatitis) do have tactile sensitivities and don’t like the way any creams, ointments, anything, feel on their skin. Thinking about a shot, even though it hurts, doing a shot once or twice a month can actually often be so much easier than having the parents have to argue with the kid two to three times a day to get the topicals on. So, I actually think of injections very quickly for patients with tactile sensitivities.” – Dr. Elizabeth SwansonPEDS25: Controlling the Wolf in Sheep’s Clothing: Managing Pediatric Atopic Dermatitis with Biologic Therapies: An Online ActivityThis activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals, Inc.